Regulation of integrin affinity (activation) is essential for metazoan development and for many pathological processes. Binding of the talin phosphotyrosine-binding (PTB) domain to integrin b subunit cytoplasmic domains (tails) causes activation, whereas numerous other PTB-domain-containing proteins bind integrins without activating them. Here we define the structure of a complex between talin and the membrane-proximal integrin b3 cytoplasmic domain and identify specific contacts between talin and the integrin tail required for activation. We used structure-based mutagenesis to engineer talin and b3 variants that interact with comparable affinity to the wild-type proteins but inhibit integrin activation by competing with endogenous talin. These results reveal the structural basis of talin's unique ability to activate integrins, identify an interaction that could aid in the design of therapeutics to block integrin activation, and enable engineering of cells with defects in the activation of multiple classes of integrins.
INTRODUCTION
Integrins are found throughout the animal kingdom, where they play important roles in cell adhesion, migration, proliferation, and survival. They are membrane-spanning heterodimers of a and b subunits, both of which typically comprise a short cytoplasmic tail ($20 to 50 residues), a single transmembrane helix, and a large extracellular domain ($700 to 1000 residues). In mammals, there are 18 identified a subunits and 8 b subunits that combine to form 24 distinct heterodimers. In humans, integrins play critical roles in development and participate in the pathogenesis of heart disease, chronic inflammation, and cancer Hynes, 2002) .
Many integrins are expressed with their extracellular domains in a default low-affinity ligand-binding state (the ''off state''); however, cells can change the conformation and affinity of these receptors in response to cellular stimulation in a process often termed ''integrin activation.'' This conformational change results in increased adhesion and subsequent signaling, which mediates events such as cell migration, platelet aggregation, leukocyte exit from the vasculature, and assembly of the extracellular matrix. The binding of a cytoskeletal protein called talin to the b subunit cytoplasmic tail is a common final step in the activation process (Tadokoro et al., 2003; Tanentzapf and Brown, 2006) .
Talin consists of a large C-terminal rod domain that contains bundles of a helices and an N-terminal FERM (band 4.1, ezrin, radixin, and moesin) domain with three subdomains: F1, F2, and F3 (Chishti et al., 1998; Garcia-Alvarez et al., 2003; Papagrigoriou et al., 2004; Rees et al., 1990) . Talin colocalizes with integrins (Horwitz et al., 1986 ) and binds to F-actin and actin-binding proteins (reviewed in Critchley, 2005) , thus linking the actin-cytoskeletal network to the extracellular matrix. The F3 subdomain of the FERM domain contains the highest affinity integrinbinding site for integrin b tails and is sufficient to activate integrins (Calderwood et al., 2002) . A partial view of this interaction was obtained in a crystal structure of the F2 and F3 domains of the talin FERM domain in complex with a 12 residue fragment ( 739 WDTANNPLYDEA 750 ) comprising $25% of the b3-integrin tail . That work confirmed that the F3 domain has a phosphotyrosine-binding (PTB) domain fold and that its interaction with integrins strongly resembles the interaction of other PTB domains with peptide ligands . Several other PTB domains bind to b3 in a similar fashion to talin Garcia-Alvarez et al., 2003) , but only talin has exhibited the capacity to activate integrins. Thus, we reasoned that additional unique features of the integrin/talin interaction enable talin to cause activation. Indeed, nuclear magnetic resonance (NMR) spectroscopic evidence has suggested an interaction between talin F3 and the membrane-proximal (MP) btail region Vinogradova et al., 2002) that is important for activation (Hughes et al., 1995; Ulmer et al., 2003) . However, such an interaction has not been directly observed.
Here, we provide the first atomic-level description of the interaction between talin and the MP region of the b3-integrin cytoplasmic domain. Structure-based mutagenesis shows that disruption of the newly identified interactions blocks integrin activation in cells while retaining binding to the membrane-distal (MD) region of b3. These results define the talin/integrin interactions that lead to integrin activation and explain why talin's activating ability is unique among PTB-containing proteins. They also identify an interaction that is a target for the rational design of therapeutics that will block integrin activation while allowing other MD-interacting proteins to maintain their functions.
The new understanding also allows the engineering of cells or animals with selective defects in integrin activation.
RESULTS

Talin Interacts with Both the MP and MD Regions of the b3 Tail
We set out to obtain a structural explanation for the unusual ability of the talin PTB domain to activate integrins. An initial exploration of the interactions was carried out by adding various tail-derived b3-integrin peptides to the F3 subdomain of talin while monitoring the chemical shift perturbations in 1 H-15 N-HSQC NMR spectra. The peptide sequences and the nomenclature used are set out in Figure 1A (D-H) Weighted shift data for each peptide titration are mapped onto the structure of the F3 subdomain with the largest shifts shown in blue (the full data set is given in Figure S1 ). peptide primarily causes chemical shift perturbations in strand S5 (de Pereda et al., 2005) . The chemical shifts for the MP peptide show that it interacts with a site on F3 that is distinct from the MD-binding site (Figure 1) . The new perturbations found in the MPbinding site mainly arise in residues that form a loop between the first and second b strands (S1 and S2) of the F3 structure. Residues 358 and 359 of F3 are also perturbed, presumably due to the b-tail residue W739 that is included in both the MP and MD peptides and binds tightly in a pocket on the surface of F3.
NMR studies of the interaction with full-length b3 cytoplasmic tails were more challenging. The off rates of the complex correspond to an ''intermediate exchange'' regime, with peaks broadening and disappearing rather than changing position. It was possible, however, to define perturbed residues by plotting the percentage decrease in peak height upon addition of the peptide (Figures 1D and S1). The perturbed residues are essentially the sum of those affected by the MD peptide and the MP peptide (Figures 1 and S1 ). The b3-tail/talin F3 interactions can thus be considered in two parts, with one corresponding to the previously defined interaction at the MD site and the other corresponding to the MP site. The limited solubility of the full-length b3 tail meant that it was not possible to produce a 1:1 complex at the concentrations used. This, together with exchange broadening of lines, made the b3 tail an unsuitable ligand for studying the structure of the talin/integrin complex by NMR at atomic resolution.
We have, however, previously shown that a peptide segment from phosphatidylinositol phosphate kinase type Ig (PIPKIg) binds in a similar manner to the b3-integrin peptide in the MD site (de Pereda et al., 2005) . These data are shown again here for comparison ( Figures 1D and S1 ). Both peptides bind to talin F3 and form a b strand followed by a reverse turn, but the PIPKIg peptide binds with much higher affinity in a slow-exchange NMR regime, and a 1:1 complex is readily achieved. Critically, W739 from the b3 tail and W642 from the PIPKIg peptide occupy essentially identical positions and adopt identical main-chain and side-chain torsion angles, each binding in a deep pocket on the talin protein surface (de Pereda et al., 2005; Garcia-Alvarez et al., 2003) . This strong similarity led us to believe that a synthetic chimeric peptide comprised of b3-integrin tail residues on the N-terminal side of the critical tryptophan and PIPKIg residues on the C-terminal side would yield a peptide ligand with higher affinity and better solubility that would be suitable for high-resolution studies of the F3-MP interaction. The sequence of the designed chimeric peptide is shown in Figure 1A . NMR experiments showed that this chimeric peptide does indeed bind to talin and forms a tight, highly soluble 1:1 complex. Moreover, comparison of the protein-backbone chemical shifts in the bound and unbound states indicates that the residues affected by the chimeric peptide are essentially the sum of residues affected by the MP-integrin peptide and those affected by the PIPKIg peptide (Figures 1 and S1 ), supporting the idea that the chimera is suitable for structural studies of the F3-MP interaction.
The Structure of the Talin F3/Peptide Complex Reveals a Binding Interface with the MP Site The structure of the complex was calculated from NMR data using a total of 2187 experimental restraints, 138 of which were unambiguous intermolecular nuclear Overhauser effects (NOEs; Table S1 and Figure 2 ). As expected, the PIPKIg-derived portion of the peptide binds in a manner very similar to that seen in the crystal structure (de Pereda et al., 2005) ; the SPLH sequence (residues 742-745) forms a reverse turn, and residues 739-741 create a b strand that augments the b sheet formed by strands S5-S7 from talin ( Figure 2) . Importantly, the pivotal tryptophan residue (W739) that connects the two sequences in the chimera aligns closely with the same residue in the crystal structure of the b3-tail complex (GarciaAlvarez et al., 2003;  Figure 2C ). This strongly suggests that residues 716-739 of the b3 tail are free to adopt their native orientation in the F3 complex. The extended nature of the complex and the relative rigidity of the F3 domain are consistent with the notion that the MD site and the MP site behave relatively independently ( Figure 2B ). Thus, any differences between the native integrin peptide and the chimeric peptide are restricted to the MD site. The structural and functional implications of differences between the binding of the PIPKIg peptide and the b-tail MD site have been discussed previously (de Pereda et al., 2005) .
The new structure reveals important novel contacts between the MP region of b3 and talin. Specifically, the b3-derived portion of the peptide forms an a helix between H722 and R736. This helix lies across strands S1-S2 and S6-S7 of the talin F3 domain and buries two phenylalanine residues of the b3 tail (F727 and F730). Of the 138 intermolecular NOEs used in the structure calculation, 57 define the MP integrin/talin interface. The majority of these involve the two phenylalanine residues F727 (23 NOEs) and F730 (18 NOEs). The hydrophobic talin residue L325 appears important for this interaction, and 7 NOEs were identified between this residue and the phenylalanine side chains (see Figure S2 ). The calculated structure is consistent with the chemical shift changes in the F3 domain observed during NMR titration experiments ( Figure S1 ).
There is a propensity for residues 722-732 of the free b3 peptide to form an a-helical structure since the a-proton chemical shifts of these residues are consistently downfield from random-coil values. Binding to the talin F3 domain further increases the downfield shifts of these b-tail resonances, which indicates that the helix is stabilized in the complex (data not shown). Heteronuclear 1 H-15 N NOEs were recorded for the protein alone as well as in complex with various peptides ( Figure S3 ). The results indicate that the loop between S1 and S2 of talin F3 is stiffened by binding to the MP region of the b3 tail, which again supports the calculated structure.
Mutation of b-MP Residues that Contact F3 Diminishes the Ability of Talin to Activate Integrin aIIbb3
Contacts between talin and the MP region of the b3 cytoplasmic tail may constitute an interaction that is a key to the activation process. To test this concept, the effects of a number of designed mutations in both the b3 tail and the talin F3 subdomain were investigated. Integrin activation was assessed using the antibody PAC1 and flow cytometry as previously described .
The effects of mutating F727 and F730, which both make intimate contact with F3, were investigated using a mutant integrin aIIb subunit, R995A. When paired with a wild-type (WT) b3 subunit, the assembled integrin is in an activated state in transfected cells ( Figure 3A ), which is consistent with previous reports (Hughes et al., 1996) . The activated state is dependent on endogenous talin, as shown by the decrease or abolition of ligand binding when the influence of talin is reduced either by talin knockdown or by a mutation in the b tail (Y747A) that disrupts talin binding (Tadokoro et al., 2003; Figure 3A) . When aIIb(R995A) was paired with b3(F727A) or b3(F730A), b3 mutants designed to disrupt the F3-MP interaction, the activating effect of the aIIb(R995A) mutation was dramatically reduced ( Figure 3B ).
Mutation of F3 Residues that Contact the b Tail Diminish the Ability of Talin to Activate Integrin aIIbb3
Mutations to the contact residues in talin F3 (L325R, S365D, S379R, or Q381V) were also made to see if they disrupted the F3-MP interaction. Mutants were correctly folded, as judged by their dispersed NMR spectra (data not shown), and chemical shifts induced by addition of chimeric peptide indicated that binding to the MD site was unchanged. In contrast, perturbation of contact residues in the MP region was either markedly reduced, as with F3(Q381V) and b3(F727A), or undetectable, as with F3(L325R) and b3(F730A) (Figure 4) . Transfection of cells with cDNA encoding the F2 and F3 subdomains (F23) of talin (residues 206-405) is known to activate several integrins (Calderwood et al., 2002) , but each of the four mutations diminished the ability of F23 to activate integrin aIIbb3 ( Figures 3C and S4 ). These results establish the biological relevance of the interactions seen between the talin F3 protein and the MP region and show that these interactions are critical for integrin activation.
Talin Mutants that Inhibit Integrin Activation
The observation that talin mutants with impaired contacts to the MP region still bind to the chimeric peptide via the MD site suggested that they might compete with and displace endogenous talin, thus inhibiting integrin activation.
To investigate this possibility, we used abPy cells from a chinese hamster ovary (CHO) cell line that expressed a talin-dependent, constitutively active chimeric integrin that was composed of the extracellular and transmembrane domains of aIIbb3 as well as the cytoplasmic tails of a6b1 (Baker et al., 1997) . We transiently transfected abPy cells with cDNAs encoding the mutant F23 constructs (A and B) CHO cells were transiently transfected with plasmids encoding aIIb and b3 or mutants thereof. In some samples (indicated above) a plasmid encoding a shRNA for talin-1 (Tadokoro et al., 2003) or a control shRNA was cotransfected with the integrin plasmids. Cells were double-stained for integrin-aIIbb3 expression (B-D57) and activated aIIbb3-(PAC1). Flow cytometry was used to measure the geometric mean fluorescence intensity (F) of PAC1 binding. Nonspecific PAC1 binding (F 0 ) was measured in the presence of a competitive antagonist of aIIbb3, Ro43-5054, and maximal binding (F max ) was measured in the presence of the activating antibody anti-LIBS6. Activation index was defined as 100 3 . Mutants to MP-contacting residues (L325R, S365D, S379R, and Q381V) and MD-contacting residues (W359A) prevent activation. (D) PAC1 binding in aIIba6b3b1-expressing abPy cells transfected with talin F23 or its mutants relative to that in cells transfected with empty vector (set as 100). The MP-contacting talin F23 mutants (L325R, S365D, S379R, and Q381V) inhibited activation, whereas the MD-contacting mutant talin F23(W359A) had no significant effect on activation levels. All data are an average of three of more measurements; error bars are standard deviations.
(L325R, S365D, S379R, or Q381V). Each of the four mutants blocked integrin activation ( Figure 3D ), a result consistent with competition between endogenous full-length talin and the activation-defective F23 mutants for binding to the b-MD site. In contrast, transfection of these cells with cDNA encoding WT F23 modestly increased activation, whereas a mutant that strongly inhibits the MD-binding site, F23(W359A), had no effect on activation, which is consistent with its markedly reduced affinity for the b tail (Table S2) .
To assess whether other PTB domains could recapitulate the dominant-negative effect of the talin mutants, abPy cells were transfected with the PTB-containing protein DOK1. As predicted, this protein inhibited integrin activation ( Figure 5A ), which is consistent with the idea that it competes with endogenous talin for the MD site but does not induce activation. Comparison of the structures of the DOK1 and talin PTB domains shows that they differ primarily in the region between strands S1 and S2 ( Figure 5B ), which is consistent with the idea that this region is vital for activation. Titration of the DOK1 PTB domain with the b3/PIPKIg peptide revealed interactions with S5, S6, and H2, which is indicative of binding to the MD region, whereas no interactions with the S1 to S2 regions were observed ( Figure 5C ). These results explain the unique ability of talin to activate integrins and provide a structural explanation for the capacity of certain other PTB-domain-containing proteins (Huang et al., 2004) to inhibit integrin function.
Thermodynamic parameters for the binding of WT and mutant talin F3 to the b3-chimeric peptides were measured using isothermal titration calorimetry (ITC ; Table S2 and Figure S5 ). In general, mutations that disrupt the MP site, either in the b tail or talin F3, have relatively little effect on the K d values (Table S2 ). This probably arises because of a balance between enthalpy gain and entropy loss, which is consistent with stabilization of the MP helix on talin binding in the WT but not in mutant structures. In sharp contrast, the talin (W359A) mutant, which inhibits binding of the MD site of the b3 tail, reduced the affinity $1000-fold, similar to the effect of mutations in the NPxY region of the integrin tail that abrogate MD binding . These results suggest that the MD site provides a substantial fraction of the binding energy and explain why other PTB domains that only bind the MD site could readily compete with talin. Talin F3 L325R and Q381V mutants were titrated with the original b3/PIPKIg chimera, while the effect of peptide mutations (F727A and F730A) was assessed using WT talin F3. The shift maps (see Experimental Procedures) indicate that binding to the MP region (via the talin loop between S1 and S2) is markedly reduced for the Q381V and F727A mutants or completely abolished for the L325R and F730A mutants, while interactions with the MD region are retained.
An Activating Mutant in the Transmembrane Domain Is Talin Independent We previously proposed that talin binding to the b subunit cytoplasmic domain results in a mismatch in the packing of the transmembrane regions of a and b subunits . Modeling and mutational approaches indicate that interactions between the transmembrane regions stabilize the integrin low-affinity state (Bennett, 2005; Gottschalk, 2005; Luo et al., 2005; Partridge et al., 2005) . Another interaction that helps maintain the inactive conformation is the aIIb(R995)/b3(D723) MP salt bridge (Hughes et al., 1996) . We note, however, that while breaking this link shifts the equilibrium toward the active state, it does not by itself promote full activation, which requires endogenous talin (Tadokoro et al., 2003) . To test if transmembrane mutations activate in a talin-independent manner, the apolar-to-charged mutation b3(L712R) was analyzed. A combination of this mutant with b3(Y747A), a mutation that prevents binding to the talin F3-MD site aIIbb3(L712R,Y747A), remained fully activated ( Figure 6A ), confirming that disruption of transmembrane helix packing activates integrin aIIbb3 independent of talin binding.
DISCUSSION
A combination of NMR studies, together with cell-based functional assays, has revealed how the talin F3 domain is uniquely designed to activate integrins. The talin F3 domain forms a well-defined complex with the helix-forming MP region of the b-integrin tail, and this interaction holds the key to the molecular recognition required for activation. Mutations in integrin or talin that inhibit this interaction in vitro also prevent integrin activation in cells, and mutants with intermediate functional effects in cells retain N-HSQC spectra on addition of the b3/PIPKIg peptide to the DOK1 PTB domain (10:1 molar ratio). Gray columns indicate residues whose peaks experienced severe line broadening in the bound state and could not be assigned.
a partial ability to form the F3-MP interaction (compare Figures 3 and 4) . These findings are consistent with previous studies that identified a variety of activating mutations within the MP region of integrins, thus establishing that this region is critical for stabilizing the low-affinity conformation Partridge et al., 2005) .
The unique feature of talin F3 that promotes interaction with the MP region of b-integrin appears to be the flexible loop between strands S1 and S2 that forms a hydrophobic pocket that accepts the side chains of F727 and F730 in the complex. The talin mutation L325R within this pocket abolishes binding to the MP region ( Figure 4 ) and thus hinders activation ( Figure 3C ). Other PTB-domain-containing proteins (DOK [''IRS-like''], Shc [''Shc-like''], and NUMB [''Dab-like'']; Uhlik et al., 2005) lack such a mobile loop and so are unlikely to interact with the MP region ( Figure 5B ). Indeed, we showed that DOK binds and inhibits integrin activation and that binding occurs to the MD site but not the MP site ( Figure 5 ). Several point mutants in talin also transform the F3 domain from an activator into an inhibitor ( Figure 3D ). This is consistent with competition between endogenous talin and various PTB domains, including mutated talin F3, for the MD site. The concept of inhibition of talin activation by competitive binding to the b tails by a variety of proteins, especially those with PTB domains, may be an important feature in the regulation of integrin activity. These conclusions also apply to PTB (F3) subdomains in other FERM-domain proteins. The FERM-domain structures of band 4.1, ezrin, radixin, and moesin all have very short loops between strands 1 and 2 with no hydrophobic residues that could bury the two integrin phenylalanines (Edwards and Keep, 2001; Hamada et al., 2000; Han et al., 2000; Smith et al., 2003) .
Integrin activation is critical for a variety of pathological events such as thrombosis, inflammation, and tumor metastasis (Campbell and Ginsberg, 2004) . The interface between the MP region of b3 and talin suggests that it might be readily accessible to pharmacological inhibition. The inhibitory talin mutants provide interesting tools to study talin, as they should maintain other talin functions, including the formation of links to the cytoskeleton and other focal adhesion proteins.
How does the talin/MP interaction lead to activation? One possibility is that the configuration of the complex disrupts the putative salt bridge between aIIb(R995) and b3(D723). Several distinct models for the a-b tail complex have been published, and the F3-MP complex would (A) CHO cells were transiently transfected with plasmids encoding aIIb and b3 or mutants thereof, and the cells were double-stained with PAC1 and D57 to measure integrin activation and aIIbb3 expression, respectively. Integrin activation was estimated as described in the legend to Figure 3 . Both the putative transmembrane-shortening b3(L712R) mutation and the salt-bridge-breaking aIIb(R995A) mutation result in an activated integrin. However, when paired with a mutation that disrupts talin binding to form aIIb(R995A)b3(Y747A), the R995A mutation loses the ability to induce the high-affinity state, whereas the b3(L712R) mutation's activation level is unchanged in the aIIbb3(L712R, Y747A) integrin. (B) CHO cells stably expressing aIIbb3 (A5 cells) were transiently cotransfected with vectors for WT or mutant HA-tagged talin F23 and eGFP protein as a transfection marker. PAC1 binding was assessed in the GFPexpressing subset of cells by flow cytometry and analyzed as described in the legend to Figure 3 . Mutation of lysine K320 (K320D), a residue that is predicted to point away from the membrane, had no effect on activation, while mutation of K322 (K322D), a residue that is predicted to be directed toward the membrane, prevented activation. The inset to (B) shows representative western blots of cell lysates probed with anti-HA antibody and indicate that WT and mutant HA-talin F23 expressed to similar levels. The data are an average of three of more measurements; error bars are standard errors of the mean.
sterically prevent the formation of the salt bridge in some of these (Gottschalk, 2005; Vinogradova et al., 2002; Weljie et al., 2002;  Table S3 ). We note, however, that while breaking this salt bridge seems to be necessary, it is not sufficient for full activation ( Figure 3A ; Tadokoro et al., 2003) . Prevention of b3 binding to the MD site by the b3(Y747A) mutation also inhibits activation of the aIIb(R995A)b3 (Figure 3 ) and b3(D723R) forms of integrin (data not shown). Talin binding to the MD site might contribute to activation by displacing this part of the integrin tail from a membrane-anchored position (Vinogradova et al., 2004) ; however, it is hard to reconcile this idea with the inactive state of the aIIb(R995A)b32(F727A) or aIIb(R995A)b3(F730A) integrins ( Figure 3B ) in spite of destabilization of the salt bridge and talin still binding via the MD site. In contrast, our data suggest that the primary function of the talin/MD interaction is to provide an initial strong linkage between talin and integrin and that activation arises from the subsequent talin/MP interaction.
We have proposed that activation involves disruption of transmembrane helix interactions . A related model with the additional possibility of homoand heterodimeric interactions has been proposed by Li et al. (2005) , and interactions between membrane-spanning regions have also been modeled (Gottschalk, 2005) and implied by leucine mutagenesis (Luo et al., 2005) . Glycosylation mapping was used to explore whether the membrane-spanning regions changed positions in the membrane (Stefansson et al., 2004) . Here we made a mutation in the membrane-spanning region, b3(L712R), which is expected to reposition the transmembrane helix, thus allowing the arginine guanidinium group to snorkel out of the bilayer into a more hydrophilic environment.
The activating yet talin-independent property of b3(L712R) (Figure 6 ) is consistent with integrin activation that involves repositioning of the b-transmembrane helix. Since in the absence of other proteins integrins are in equilibrium between the inactive and active states, one possibility is that the b-integrin subunit transmembrane domain is dynamic, bobbing in and out of the membrane, with its transmembrane helices sampling various degrees of burial within the bilayer. Formation of a stable MP-b3 helix in intimate contact with talin F3 would promote a conformation in which transmembrane domain residues are further out of the membrane than in the ''off state,'' pushing the equilibrium toward the active conformation.
The structure-function analysis reported here provides a cogent structural model to explain talin-dependent integrin activation (Figure 7) . When the F3 domain engages the b-MP region, additional favorable electrostatic contacts between F3 and the lipid head groups can be made. For example, two lysine residues (316 and 322) within the large S1-S2 loop, which contacts the N-terminal end of the b-MP helix, would point toward the acidic head groups of the membrane bilayer. K343 and K345 from the flanking loop also contribute to making the MP surface of talin F3 highly basic. When the b-MP and transmembrane regions are modeled as a continuous a helix and the F3 lysines are brought into apposition with a model membrane (Figure 7) , the last predicted residue to lie within the bilayer is H722, in agreement with glycosylation-mapping studies (Stefansson et al., 2004) . To test this model, we mutated two basic residues in the S1-S2 loop: mutation of K322 (K322D), which points toward the bilayer in our model, prevented talin activation, while mutation of K320 (K320D), which points away from the bilayer, had no effect ( Figure 6B ). We speculate, therefore, that F3-membrane interactions, together with the formation of a b-tail helix in intimate contact with F3, make significant contributions to the energy required to stabilize the integrin-activated state. In the context of a complete FERM domain, the orientation and location of F3, in which the MP helix points vertically through the membrane, also bring the surfaces of the F1 and F2 domains into close apposition with the membrane. We note that in the F2 domain, four lysines (263, 268, 272, and 274 ) also appear appropriately positioned to interact with the membrane. This orientation of the FERM domain on the membrane surface is similar to that proposed previously for a radixin-ICAM-2 complex (Hamada et al., 2003) .
In summary, we have demonstrated the structural basis for the unique ability of talin to activate integrins. The specific interface identified here completes the molecular picture of the talin/b3 interaction and provides a target for the design of therapeutics aimed at disrupting integrin activation while leaving talin's other activities intact. Finally, we provide a structural template for mutational studies to define the biological role of talin's ability to activate integrins in cells and, ultimately, in whole animals.
EXPERIMENTAL PROCEDURES
Peptides
Peptides were synthesized commercially by Alta Bioscience (Birmingham, England, UK) or EZBiolab (Westfield, IN, USA) or produced as a GST-b3 recombinant fusion protein with the peptide liberated by thrombin digestion. All peptides were further purified using reversephase high-performance liquid chromatography and validated by electrospray-ionization mass spectrometry.
Labeled-Protein Preparation U-
15 N-labeled talin F3 domain was expressed and purified as described previously (de Pereda et al., 2005) . U-15 N-labeled DOK1 PTB domain (residues 154-256; Swiss-Prot Q99704) was subcloned into the pGEX-6P2 vector and produced using the same methods. U-15 N, 13 C and U-15 N, 2 H doubly labeled talin was produced in the same way, using 13 C-glucose or D6-glucose and D 2 O.
NMR Spectroscopy
All NMR experiments were carried out at 25 C on spectrometers equipped with Oxford Instruments superconducting magnets (500, 600, and 750 MHz 1 H operating frequencies) and GE Omega (Redfield et al., 1991) . Heteronuclear 15 N-1 H-NOEs were determined from a pair of HSQC experiments recorded with and without 1 H saturation during the recycle delay (Farrow et al., 1994) . NMR experiments were processed using NMRPipe (Delaglio et al., 1995) and visualized with Sparky (www.cgl.ucsf.edu/home/ sparky).
Structure Calculation NOE distance restraints were calibrated on the basis of NOEs from regular secondary-structure elements and were grouped into four classes (1.8-3.0 Å , 1.8-3.8 Å , 1.8-4.6 Å , and 1.8-6.0 Å ) corresponding to strong, medium, weak, and very weak NOEs. Dihedral restraints (F/c) were obtained from the TALOS database (Cornilescu et al., 1999) . Additional F angle restraints were derived from the 3 J HNHAcoupling constants and a modified Karplus equation (Pardi et al., 1984) . Hydrogen-bond restraints were incorporated based on hydrogen-exchange data and secondary-structure elements identified from initial rounds of structure calculation. Structure calculations were performed using a simulated annealing protocol within the program CNS, Version 1.1 (Brunger et al., 1998) . The initial conformation of the talin F3 domain was that from the crystal structure of talin in complex with the PIPKIg peptide (de Pereda et al., 2005) , while the chimera peptide started from randomized coordinates. One hundred structures were calculated, and the top 20 of these were further refined. Floating assignment of prochiral groups was achieved using the SOPHIE procedure (Pickford et al., 2001 ). During final minimization each group was eased into the pro-R or pro-S position by enforcing the correct bond angles at the prochiral center. The stereochemical quality of the structures was assessed using the program PROCHECK-NMR (Laskowski et al., 1996) . Molecular models were generated using the program MOLMOL (Koradi et al., 1996) .
Cell Culture, Cell Lines, and Reagents CHO cells were obtained from American Type Culture Collection (ATCC) and cultured in Dulbecco's Modified Eagle's Medium with 10% fetal bovine serum (FBS), 1% nonessential amino acids (Sigma), penicillin (50 units/ml), and streptomycin sulfate (50 mg/ml) in a 37 C tissue-culture incubator. The anti-aIIbb3 antibodies D57, PAC1, and anti-LIBS6, as well as Ro43-5054, an aIIbb3-specific peptide-mimetic competitive inhibitor, have been described (Tadokoro et al., 2003) . The D57 antibody was biotinylated with biotin-N-hydroxy-succinimide (Sigma; B-D57) according to the manufacturer's instructions.
Site-Directed Mutagenesis
Site-directed mutations in both the aIIbb3 subunits and the talin F3 construct were generated using the QuikChange mutagenesis kit (Stratagene). Mutants were confirmed by DNA sequencing.
Flow Cytometry
For experiments to assess the functional effect of point mutants in the b3 tail, CHO cells were cotransfected with pCDM8 plasmids coding for WT or mutant sequences of aIIb and b3. Transfection was done using the Plus Reagent and Lipofectamine (Invitrogen Life Technologies); 24 hr later cells were stained with B-D57 and PAC1 in the presence and absence of Ro43-5054 or anti-LIBS6. The biotinylated monoclonal antibody B-D57 was used to detect expression of aIIbb3, while PAC1, an activation-specific, monoclonal IgM antibody, was used to assess the activation state of the aIIbb3 integrin. This antibody is an authentic ligand for integrin aIIbb3 (Abrams et al., 1994) , and its binding correlates with the binding of natural ligands such as fibrinogen (Shattil et al., 1985) . Cells were analyzed on a FACScan using both B-D57 and PAC1 antibodies as described previously . The geometric mean fluorescence intensity (MFI) of PAC1 staining in the presence of Ro43-5054 (2 mM) was used to estimate nonspecific PAC1 binding (F 0 ). The fluorescence intensity in the presence of anti-LIBS6 was used to estimate maximal PAC1 binding (F max ) since anti-LIBS6 directly induces aIIbb3 binding to PAC1 regardless of the status of cellular activation mechanism (Baker et al., 1997) . The activation index was calculated using the formula: 100 3 (F À F 0 ) / (F max À F 0 ), where F = MFI under the test condition. For experiments to assess the functional effect of F3-domain mutations, WT or mutant versions of pCDNA3.1 plasmids coding for N-terminally HA-tagged proteins consisting of the F2 and F3 domains of mouse talin (residues 206-405; Swiss-Prot P26039) were transiently transfected into cells stably expressing WT aIIbb3, an aIIb(D723A)b3 mutant or an aIIba6Ab3b1A-chimeric integrin (abPy cells; Baker et al., 1997) . In these experiments eGFP vector was cotransfected as a transfection marker at a HA-F23/eGFP ratio of 20:1.
Calorimetry ITC was performed on a VP-ITC calorimeter (Microcal, Northampton, MA, USA). Aliquots (8 ml) of WT (KKLLITIHDRKEFAKFEEERARAKWVpYSPLHYSAR) or mutant chimeric peptide were injected into the cell containing WT or mutant talin F3 domain. Peptide concentrations were typically 150 to 300 mM, while protein concentrations ranged from 25 to 50 mM. For the W359A mutant, the protein concentration was 50 mM, and the peptide concentration was 1 mM. Prior to ITC titrations, the peptides and proteins were in 200 mM Tris, 300 mM NaCl, pH 7.5. In each experiment 37 injections were made. The experiments were performed at 23 C. All titrations were performed at least twice and with different protein preparations. Experimental data were analyzed using MicroCal Origin software. 
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